Glimihop PM 1mg/500mg/15mg Tablet ER
Marketer
Anax Lifescience
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Glimihop PM 1mg/500mg/15mg Tablet ER
Combiflex DM, a 1mg/500mg/15mg extended-release tablet, manages blood glucose in adults with type 2 diabetes. Used alongside diet and exercise, it enhances insulin effectiveness, reducing blood sugar. Dosage and duration should strictly follow your physician's instructions; take with food to minimize gastrointestinal discomfort. Missed doses should be taken promptly unless nearing the next scheduled dose; never double the dose. Overdosage can cause dangerously low blood sugar (hypoglycemia). Concomitant use with other diabetes medications, alcohol, or skipped meals increases hypoglycemia risk; regular blood sugar monitoring is crucial. Common side effects include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Pre-existing kidney, liver, or heart conditions should be disclosed to your doctor before commencing treatment, as should pregnancy or breastfeeding. Kidney function tests will be conducted prior to treatment initiation. Limit alcohol consumption to mitigate potential side effects.
Primary Ingredients of Glimihop PM 1mg/500mg/15mg Tablet ER
There is no text provided to rephrase.
Uses of Glimihop PM 1mg/500mg/15mg Tablet ER
Managing Type 2 diabetes
Major Benefits of Glimihop PM 1mg/500mg/15mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Glimihop PM 1mg/500mg/15mg Extended-Release tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with food.
Common Side effects of Glimihop PM 1mg/500mg/15mg Tablet ER:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Glimihop PM 1mg/500mg/15mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment schedule. Ingest the Glimihop PM 1mg/500mg/15mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with food.
How Glimihop PM 1mg/500mg/15mg Tablet ER works:
Glimihop PM 1mg/500mg/15mg Extended-Release tablets combine glimepiride, metformin, and pioglitazone—three distinct antidiabetic agents—to optimize blood glucose management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion, thus reducing blood glucose levels. Metformin, a biguanide, acts through multiple pathways: decreasing hepatic glucose production, slowing intestinal glucose absorption, and enhancing insulin responsiveness. Pioglitazone, a thiazolidinedione, further amplifies insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimihop PM 1mg/500mg/15mg Extended-Release Tablets with alcohol is hazardous.
PregnancyCONSULT YOUR DOCTOR
The extended-release Glimihop PM 1mg/500mg/15mg tablet might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glimihop PM 1mg/500mg/15mg tablets are likely unsafe for breastfeeding mothers. Available evidence from human studies indicates potential drug transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Impaired driving may result from excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.
KidneyCAUTION
Patients with kidney impairment should use Glimihop PM 1mg/500mg/15mg Extended-Release tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. This medication is contraindicated in patients with severe kidney disease. Regular monitoring of renal function is recommended during treatment.
LiverCAUTION
Patients with liver impairment should use Glimihop PM 1mg/500mg/15mg Extended-Release tablets cautiously, as dose modification may be necessary. Consult a physician for guidance. Glimihop PM 1mg/500mg/15mg Extended-Release tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Glimihop PM 1mg/500mg/15mg Tablet ER :
Should you forget to take a Glimihop PM 1mg/500mg/15mg Extended-Release tablet, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimihop PM 1mg/500mg/15mg Tablet ER
| Label | Value |
|---|---|
| Potential for Dependence | None. |
| Type of Medication | Diabetes medication |
3,018 People bought this recently